Pharmacological action
An antihypertensive agent, angiotensin II receptor antagonist. Blocks AT1 receptors, which leads to a decrease in the biological effects of angiotensin II (mediated by receptors of this type), including vasoconstrictor action, stimulating effect on the release of aldosterone, regulation of salt and water homeostasis and stimulation of cell growth. The antihypertensive effect is due to a decrease in total peripheral vascular resistance without a reflex increase in heart rate.
Does not inhibit ACE. Does not interact with or block receptors of other hormones or ion channels that are important for regulating the functions of the cardiovascular system.
Indications for the active ingredients of the drug:
Arterial hypertension; chronic heart failure and impaired left ventricular systolic function (decrease in LVEF <40%) as an adjunctive therapy to ACE inhibitors or in case of intolerance to ACE inhibitors.
Dosage regimen
The method of administration and dosage regimen of a specific drug depend on its release form and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a specific drug with the indications for use and dosage regimen.
Contraindications for use
Hypersensitivity to candesartan; pregnancy, breastfeeding; severe liver dysfunction and/or cholestasis; age under 18 years (efficacy and safety have not been established). Use of candesartan in combination with drugs containing aliskiren in patients with diabetes mellitus and/or moderate to severe renal impairment (SCF less than 60 ml/min/1.73 m2 of body surface area). Concomitant use with ACE inhibitors in patients with diabetic nephropathy.
With caution: severe renal impairment (creatinine clearance less than 30 ml/min); bilateral renal artery stenosis or stenosis of the artery to a single kidney; hemodynamically significant stenosis of the aortic and/or mitral valves; conditions after kidney transplantation in history; hemodialysis; cerebrovascular disorders of ischemic genesis and ischemic heart disease; hyperkalemia; in patients with reduced circulating volume; primary hyperaldosteronism; hypertrophic obstructive cardiomyopathy.
Use during pregnancy and breastfeeding
Candesartan is contraindicated for use during pregnancy and lactation (breastfeeding).
Use in case of liver dysfunction
Contraindicated in case of severe liver dysfunction and/or cholestasis.
Use in renal impairment
Contraindicated in patients with moderate or severe renal impairment (glomerular filtration rate less than 60 ml/min/1.73 m2 of body surface area). Use with caution in patients with renal impairment (creatinine clearance less than 30 ml/min); with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney; with primary hyperaldosteronism; conditions after a kidney transplant in anamnesis; hemodialysis.
When used in patients with renal insufficiency, potassium and creatinine levels in the blood plasma should be periodically monitored.
Use in children
Contraindicated in children and adolescents under 18 years of age.
Use in elderly patients
Caution should be exercised in elderly patients to avoid worsening of concomitant diseases. It is necessary to periodically monitor renal function, especially in patients aged 75 years and older.
Warning: Always consult a doctor before using medications.
